IFNB1 and cancer: Up-regulation of PD-L1 is a major obstacle in IFN-β based cancer immunotherapy as it can lead to T cell anergy and apoptosis through interaction with PD-1 [34, 35], but can also down-modulate T cell effector activities [36].